Biologically, the coexistence of MSI-H and deleterious DNA damage response (DDR) pathway mutations (BRCA2 and ATM) may drive a hypermutated phenotype, as reported in subsets of colorectal and endometrial cancers. The gene discussed is ATM; the disease is endometrial cancer.